Skip to main content
PMC home page
Frontiers in Cell and Developmental Biology logoLink to Frontiers in Cell and Developmental Biology
. 2021 Jun 11;9:690522. doi: 10.3389/fcell.2021.690522

X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis

Soudeh Ghafouri-Fard 1, Sepideh Dashti 1, Molood Farsi 2, Mohammad Taheri 3,*, Seyed Ali Mousavinejad 4,*
PMCID: PMC8226258  PMID: 34179019

Abstract

X-inactive–specific transcript (XIST) is one of the firstly discovered long non-coding RNAs with prominent roles in the process of X inactivation. Moreover, this transcript contributes in the carcinogenic process in different tissues. In addition to interacting with chromatin modifying molecules, XIST can be served as a molecular sponge for miRNAs to modulate expression of miRNA targets. Most of the studies have indicated an oncogenic role for XIST. However, in prostate cancer, a single study has indicated a tumor suppressor role for this lncRNA. Similar result has been reported for XIST in oral squamous cell carcinoma. In hepatocellular carcinoma, breast cancer, ovarian cancer, osteosarcoma, and renal cell carcinoma, different studies have reported inconsistent results. In the present manuscript, we review function of XIST in the carcinogenesis.

Keywords: lncRNA, X-inactive-specific transcript, expression, biomarker, cancer

Introduction

X-inactive–specific transcript (XIST) RNA is among the firstly discovered long non-coding RNAs (lncRNAs) in humans (Brown et al., 1992). The gene coding this lncRNA has at least eight exons and spans an area of about 17 kb on the X chromosome, in a region containing the X inactivation center (Brown et al., 1992). XIST RNA is primarily localized in the nucleus to a location not discriminable from the X inactivation-associated Barr body (Brown et al., 1992). The first important function attributed to XIST has been related to the process of X inactivation during which XIST induces gene silencing through recruitment of several chromatin modifying molecules (Loda and Heard, 2019). The indispensable role of Xist in X inactivation has been proved by targeted mutagenesis and transgenic experiments in mice showing skewing of this process following deletion of the Xist gene (Penny et al., 1996; Marahrens et al., 1997). Several molecules have been identified to interact with XIST to contribute in chromosome-wide gene silencing. SPEN, RBM15, WTAP, hnRNP K, and LBR are among molecules that participate in this process through interplay with XIST (Chu et al., 2015; McHugh et al., 2015). In addition, XIST has a prominent role in the carcinogenic processes. Several in vitro, in vivo, and clinical investigations have verified this aspect of XIST functions. In the present manuscript, we review function of XIST in the carcinogenesis.

Cell Line Studies

Breast Cancer

Functional impact of XIST in the breast carcinogenesis has been assessed in a number of in vitro studies. Liu et al. (2020) have reported down-regulation of XIST and UBAP1 in breast cancer cells. Forced up-regulation of XIST has attenuated proliferation, migration and invasion of these cells, and accelerated cell apoptosis. From a mechanistical point of view, XIST can interact with miR-362-5p and miR-362-5p to exert its effects. UBAP1 has been identified as miR-362-5p target, thus XIST modulates expression this protein via sponging miR-362-5p (Liu et al., 2020). Li et al. (2020d) have demonstrated down-regulation of XIST in triple negative breast cancer cells. Up-regulation of XIST has blocked cell proliferation and epithelial mesenchymal transition (EMT) while inducing apoptosis in these cell lines. miR-454 has been identified as a target of XIST in these cells (Li et al., 2020d). On the other hand, Zong et al. (2020) XIST has reported up-regulation of XIST in breast cancer cells, parallel with down-regulation of miR-125b-5p and up-regulation of NLRC5. XIST silencing has remarkably suppressed cell proliferation, migration, and invasion aptitudes of breast cancer cells. XIST has been shown to sponge miR-125b-5p and subsequently influence NLRC5 expression (Zong et al., 2020). Moreover, expression of XIST has been reported to be higher in doxorubicin-resistant breast cancer cells compared with parental cells. Furthermore, XIST up-regulation enhances cell proliferation and prohibited apoptosis of doxorubicin-treated breast cancer cells through enhancing expression of ANLN. XIST functions as a sponge for miR-200c-3p, which regulates expression of ANLN (Zhang et al., 2020). Figure 1 depicts different roles of XIST in the breast carcinogenesis.

FIGURE 1.

FIGURE 1

Open in a new tab

Different studies have shown the tumor suppressor role of XIST in breast cancer through sponging miRNAs (Li et al., 2020d; Liu et al., 2020) and regulating expression of epithelial-mesenchymal transition (EMT) markers (right panel). On the other hand, other studies have reported oncogenic roles for XIST (Zong et al., 2020) (left panel).

Gastric Cancer

In gastric cancer, XIST has been shown to exert oncogenic effects. Zheng et al. (2020) have demonstrated over-expression of XIST and down-regulation of miR-337 in these cells. XIST silencing has simultaneously suppressed proliferation, invasion, and migration of gastric cancer cells. Mechanistically, XIST increases expression of JAK2 through sponging miR-337 (Zheng et al., 2020). Consistently, over-expression of XIST in gastric cancer cells has been accompanied by up-regulation of PXN while down-regulation of miR-132. Furthermore, both XIST silencing and miR-132 over-expression could inhibit gastric cancer cell proliferation and migration (Li et al., 2020a). In this kind of cancer, XIST has also been shown to promote cell cycle progression at G1/S phase and block cell apoptosis through repressing miR-497 expression and up-regulating MACC1 levels (Ma et al., 2017). XIST can also sponge miR-185 to influence expression of TGF-β1 in gastric cancer cells (Zhang et al., 2018). Figure 2 depicts the role of XIST in gastric carcinogenesis.

FIGURE 2.

FIGURE 2

Open in a new tab

XIST can affect gastric carcinogenesis through sponging a number of miRNAs, thus regulating NF-κB and PI3K/AKT pathways (Chen et al., 2016; Lu et al., 2017; Ma et al., 2017; Zhang et al., 2018; Li et al., 2020a; Zheng et al., 2020).

Colorectal Cancer

Expression of XIST has been increased in colon cancer cells. Mechanistically, XIST sponges miR-34a and increases expression of WNT1. XIST also affects expression of β-catenin, cyclinD1, c-Myc, and MMP-7 in colon cancer cells (Sun et al., 2018). Moreover, expression of this lncRNA has been up-regulated 5-Flurouracil-resitant colon cancer cells. XIST silencing has inverted resistance phenotype in these cells. XIST has been shown to promote expression of thymidylatesynthase, an enzyme which is targeted by 5-Flurouracil (Xiao et al., 2017). Another study in colon cancer cells has demonstrated over-expression of XIST and FOXK1, while down-regulation of miR-497-5p. This study has also confirmed the significance of XIST/miR-497-5p/FOXK1 in the pathogenesis of colon cancer (Wang et al., 2020b). Figure 3 depicts the downstream targets of XIST in colon cancer cells.

FIGURE 3.

FIGURE 3

Open in a new tab

Downstream targets of XIST in colon cancer cells (Chen et al., 2017; Song et al., 2017; Xiao et al., 2017; Liu et al., 2020; Sun et al., 2018; Liu et al., 2019; Wang et al., 2020b). XIST enhances proliferation and epithelial–mesenchymal transition of colon cancer cells via sequestering miR-486-5p and increasing expression neuropilin-2 (Liu et al., 2019). It can also sequester miR-137 and subsequently increase expression of EZH2 to enhance metastatic ability of colon cancer cells (Liu et al., 2018).

Pancreatic Cancer

XIST has also been up-regulated in prostate cancer cell lines where it enhances their proliferation, migration and invasion, and suppresses cell their apoptosis. These effects are exerted through sponging miR-34a-5p (Sun et al., 2018). In these cells, XIST has also interactions with miR-137 through which it regulates expression of Notch1 (Liu et al., 2020). miR-141-3p is another miRNA which has been shown to be sponged by XIST in pancreatic cancer cells. XIST enhances expression of TGF-β2 through interacting with this miRNA (Sun and Zhang, 2019). Figure 4 depicts the interaction between XIST and miRNAs as well as their targets in pancreatic cancer cells.

FIGURE 4.

FIGURE 4

Open in a new tab

The interaction between XIST and miRNAs as well as their targets in pancreatic cancer cells (Liang et al., 2017; Wei et al., 2017; Sun et al., 2018; Shen et al., 2019; Sun and Zhang, 2019; Liu et al., 2020; Zou et al., 2020). XIST interaction with miR-140 and miR-124 increases expression of iASPP and promotes growth of pancreatic cancer cells (Liang et al., 2017). XIST also enhances expression of TGF-β2 through sequestering miR-141-3p. This interaction enhances invasiveness of pancreatic cancer cells (Sun and Zhang, 2019).

Bladder Cancer

In bladder cancer cells, XIST serves as a molecular sponge for miR-200c through which it enhances colony formation, self-renewal capacity and EMT in cancer stem cells -like cells (Xu et al., 2018). Another study has indicated parallel over-expressions of XIST and androgen receptor (AR) in bladder cancer cells. Mechanistically, XIST increases AR expression though sponging miR-124 (Xiong et al., 2017). Moreover, XIST can promote proliferation and metastatic ability of bladder cancer cells via modulating miR-139-5p expression and subsequent regulation of Wnt/β-catenin signaling pathway (Hu et al., 2017). Figure 5 depicts the interactions between XIST and miRNAs in bladder cancer cells.

FIGURE 5.

FIGURE 5

Open in a new tab

The interactions between XIST and miRNAs in bladder cancercells (Hu et al., 2017, 2019; Xiong et al., 2017; Xu et al., 2018; Zhou et al., 2019b). XIST influences progression of bladder cancer through suppressing p53 via binding to TET1 (Hu et al., 2019). Another route of participation of XIST in tumor growth and metastasis is exerted through regulation of miR-139-5p and Wnt/ β-catenin pathway (Hu et al., 2017).

Glioma

In glioma cells, XIST can modulate metabolism of glucose. XIST silencing has suppressed viability, migration, invasiveness, hypo-responsiveness to apoptotic stimuli, and glucose metabolism in glioblastoma. Mechanistically, XIST functions as a molecular sponge for miR-126 to subsequently regulate IRS1/PI3K/Akt pathway (Cheng et al., 2020). Another study in glioblastoma has shown the role of Steroid receptor coactivator-1 (SRC-1) in the regulation of XIST at posttranscriptional level. In fact, the impact of SRC-1 in enhancement of stemness features in glioblastoma is mediated through XIST. SRC-1 enhances expression of Kruppel-like factor 4 (KLF4) via the XIST/miR-152 axis (Gong et al., 2020). Moreover, miR-204-5p has been identified as another target of XIST in glioma cells. Interaction between XIST and miR-204-5p regulates expression of Bcl-2 (Shen et al., 2020). Figure 6 shows the interactions between XIST and miRNAs in glioma cells.

FIGURE 6.

FIGURE 6

Open in a new tab

The interactions between XIST and miRNAs in glioma cells. XIST enhances glioma tumorigenic capacity and angiogenesis through sequestering miR-429 (Cheng et al., 2017). In addition, through sequestering miR-126, XIST regulates cell proliferation and glucose metabolism of glioma cells via influencing IRS1/PI3K/Akt axis (Cheng et al., 2020). The sponging effect of XIST on miR-29c modulates resistance of glioma cell to Temozolomide via DNA mismatch repair pathway (Du et al., 2017).

Lung Cancer

XIST has also been shown to be over-expressed in lung cancer cell lines promoting their proliferation ability through sponging miR-140. XIST silencing has repressed proliferation and enhanced apoptosis of lung cancer cells. Besides, inhibitor of apoptosis-stimulating protein of p53 (iASPP) has a prominent role in mediation of this effect (Tang et al., 2017). Expression of XIST expression has also been up-regulated in cisplatin-resistant lung cancer cells compared with the original cells. Up-regulation of this lncRNA has enhanced resistance to cisplatin through blocking apoptosis and increasing proliferation ability. These effects are mediated through sponging let-7i and regulating expression of BAG-1 (Sun et al., 2017). Figure 7 shows the interactions between XIST and miRNAs in lung cancer cells.

FIGURE 7.

FIGURE 7

Open in a new tab

The interactions between XIST and miRNAs in lung cancer cells. XIST has an oncogenic role in lung cancer through different mechanisms including epigenetically silencing of KLF2 expression (Fang et al., 2016). Moreover, it can enhance viability and invasiveness of lung cancer cells through regulation of miR-137/PXN axis (Jiang et al., 2018). XIST can also enhance TGF-β-associated epithelial-mesenchymal transition through regulation of miR-367/141-ZEB2 (Li et al., 2018).

In addition to these types of malignancies, functional studies have verified the impact of XIST in the pathogenesis of almost all kinds of neoplasms. Supplementary Table 1 summarizes the results of in vitro studies.

Animal Studies

In line with in vitro studies, abnormal expression of XIST affects tumorigenesis in animal models of cancer. Almost all studies have indicated that up-regulation of XIST enhances tumorigenic ability of cancer cells, while its silencing has the opposite effects (Table 1). However, XIST has a tumor suppressor role in animal models of oral squamous cell carcinoma and renal cell carcinoma. Most notably, animal studies in hepatocellular carcinoma, breast cancer, ovarian cancer and osteosarcoma have indicated inconsistent results regarding the role of XIST (Table 1).

TABLE 1.

Outcomes of studies which evaluated function of XIST in animal models (Δ: knock down or deletion).

Cancer type Animal models Results References
Bladder cancer NOD/SCID mice Δ XIST: ↓ tumorigenesis Xu et al., 2018
BALB/C nude mice Δ XIST: ↓ tumorigenesis Hu et al., 2017
Nude mice Δ XIST: ↓ tumorigenesis, ↑ PD sensitivity Chen et al., 2020
Nasopharyngeal carcinoma BALB/c nude mice Δ XIST: ↓ tumorigenesis Cheng et al., 2018
BALB/c nude mice Δ XIST: ↓ tumorigenesis Zhao et al., 2020
Nude mice Δ XIST: ↓ tumorigenesis Shi et al., 2020
Laryngeal squamous cell carcinoma Nude mice Δ XIST: ↓ tumorigenesis Liu et al., 2020
Oral squamous cell carcinoma Nude mice ↑ XIST: ↓ tumorigenesis Li et al., 2020c
Esophageal squamous cell carcinoma BABL/c nude mice Δ XIST: ↓ tumorigenesis Wu et al., 2017
Gastric cancer BALB/c nude mice Δ XIST: ↓ tumorigenesis Li et al., 2020a
BALB/c-nu/nu mice Δ XIST: ↓ tumorigenesis, ↓ invasion Ma et al., 2017
BABL/c athymic nude mice Δ XIST: ↓ tumorigenesis, ↓ metastasis Chen et al., 2016
BALB/c-nu/nu nude Δ XIST: ↓ tumorigenesis Li et al., 2020b
Colorectal cancer BALB/C nude mice Δ XIST: ↓ tumorigenesis Sun et al., 2018
BALB/c nude mice Δ XIST: ↓ tumorigenesis Wang et al., 2020b
BALB/C nude mice Δ XIST: ↓ tumorigenesis Yang et al., 2020
BALB/c nude mice Δ XIST: ↑ anti-tumor effect of DOX, ↓ tumorigenesis Zhuang et al., 2016
Athymic nude mice Δ XIST: ↓ tumorigenesis, ↓ metastasis Chen et al., 2017
Pancreatic cancer Nude mice Δ XIST: ↓ tumorigenesis Sun et al., 2018
Nude mice Δ XIST: ↓ tumorigenesis Liu et al., 2020
Nude mice Δ XIST: ↓ tumorigenesis Liang et al., 2017
Hepatocellular carcinoma Nude mice Δ XIST: ↓ tumorigenesis Kong et al., 2018
BALB/c-nu/nu mice Δ XIST: ↓ tumorigenesis Mo et al., 2017
BALB/c thymus-free nude mice ↑ XIST: ↓ tumorigenesis Zhang et al., 2019
Nude mice ↑ XIST: ↓ tumorigenesis Lin et al., 2018
Renal cell carcinoma BALB/C mice ↑ XIST: ↓ tumorigenesis Sun et al., 2019
Lung cancer BALB/c nude mice ↑ XIST: ↑ tumorigenesis, ↑ cisplatin resistance Sun et al., 2017
Non-small cell lung cancer BABL/c athymic nude mice Δ XIST: ↓ tumorigenesis Jiang et al., 2018
Nude mice Δ XIST: ↓ tumorigenesis Qiu et al., 2019
BALB/c nude male mice Δ XIST: ↓ tumorigenesis, ↑ DDP chemosensitivity Xu et al., 2020
BALB/c nude mice Δ XIST: ↓ tumorigenesis Zhang et al., 2017
Nude mice Δ XIST: ↓ tumorigenesis Zhou et al., 2019c
BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↓ liver metastasis Wang et al., 2019
BALB/c nude mice Δ XIST: ↓ tumorigenesis Fang et al., 2016
BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↓ DDP chemoresistance Tian et al., 2019
BALB/c nude mice Δ XIST: ↓ tumorigenesis Jiang et al., 2020
Nude mice Δ XIST: ↓ pulmonary metastasis Li et al., 2018
Nude mice Δ XIST: ↓ tumorigenesis Wang et al., 2017
Breast cancer BALB/c nude mice ↑ XIST: ↓ tumorigenesis Li et al., 2020d
Nude mice Δ XIST: ↑ tumorigenesis, ↑ brain metastasis, ↑EMT, ↑ stemness Xing et al., 2018
BALB/c nu/nu mice Δ XIST: ↑ tumorigenesis, ↑ migration Zhao et al., 2020
BALB/c nude mice ↑ XIST: ↓ tumorigenesis Liu et al., 2020
Ovarian cancer Athymic nude mice ↑ XIST: ↓ tumorigenesis, ↑ cisplatin chemosensitivity Wang et al., 2018
Nude mice ↑ XIST: ↓ tumorigenesis, ↑ paclitaxel sensitivity, ↓ CD44 + /CD24-population cells Huang et al., 2020
BALB/c mice ↑ XIST: ↓ tumorigenesis Guo et al., 2021
Prostate cancer BALB/C nude mice ↑ XIST: ↓ tumorigenesis Du et al., 2017
Osteosarcoma BALB/c nude mice ↑ XIST: ↓ tumorigenesis Zhang and Xia, 2017
BALB/C nude mice Δ XIST: ↓ tumorigenesis Xu et al., 2017
BALB/c athymic nude mice Δ XIST: ↓ tumorigenesis Gao et al., 2019
BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↓ metastasis Yang et al., 2018
Glioma BALB/c nude mice Δ XIST: ↓ tumorigenesis Cheng et al., 2020
BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↑ survival time Shen et al., 2020
BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↓ angiogenesis Cheng et al., 2017
BALB/C athymic nude mice Δ XIST: ↓ tumorigenesis, ↑ survival time Yao et al., 2015
Nude mice Δ XIST: ↓ tumorigenesis Wang et al., 2020c
Thyroid cancer Athymic nude mice Δ XIST: ↓ tumorigenesis Liu et al., 2018
Acute myeloid leukemia BALB/c nude mice Δ XIST: ↓ tumorigenesis Wang et al., 2020a
Retinoblastoma BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↑ VCR sensitivity Yao et al., 2020
Cervical cancer Athymic BALB/c mice Δ XIST: ↓ tumorigenesis, ↓ EMT Chen et al., 2019
Nude mice Δ XIST: ↓ tumorigenesis Liu et al., 2020
Neuroblastoma BALB/c nude mice Δ XIST: ↓ tumorigenesis, ↑ survival time Zhang et al., 2019
BALB/c nude mice Δ XIST: ↓ tumorigenesis Yang et al., 2020
Chordoma Nude mice Δ XIST: ↓ tumorigenesis, ↑ apoptosis Hai et al., 2020
Open in a new tab

Human Studies

Experiments in clinical samples obtained from patients have shown that expression of XIST is principally increased in tumoral samples compared with nearby non-cancerous samples (Supplementary Table 2). However, in oral squamous cell carcinoma, its expression has been decreased (Li et al., 2020c). In hepatocellular carcinoma, most of studies have indicated its down-regulation (Chang et al., 2017; Lin et al., 2018; Zhang et al., 2019). However, few studies have reported opposite results (Mo et al., 2017; Kong et al., 2018). Similarly, different studies in breast cancer, ovarian cancer, osteosarcoma and renal cell carcinoma(Supplementary Table 2) have reported inconsistent results. Moreover, expression levels of XIST have been correlated with patients’ survival in different kinds of cancers including bladder cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, lung cancer, gastric cancer, colorectal cancer and breast cancer.

In nasopharyngeal carcinoma, XIST expression levels could differentiate tumoral tissues from nearby non-cancerous samples with diagnostic power of 0.813 (Song et al., 2016). In colorectal cancer, up-regulation of XIST in extracellular vesicles isolated from serum samples had an appropriate diagnostic value [Area under curve (AUC) = 0.86, sensitivity = 0.88 and specificity = 0.90]. Most notably, over-expression of XIST in serum extracellular vesicles has been associated with survival rates (Yu et al., 2020). Expression levels of XIST have also been shown to be appropriate markers for follow-up of patients with lung cancer, since they have been reduced following surgical removal of tumors. Receiver operating characteristic curves have demonstrated the ability of XIST expression levels in separation between the patients and healthy controls with an AUC value of 0.834. In addition, combination of expression levels of XIST and HIF1A-AS1 in serum samples has enhanced the diagnostic power (Tantai et al., 2015). Finally, serum levels of XIST could separate breast cancer patients from healthy controls with AUC value of 0.78 (Zhao et al., 2018). Table 2 summarizes the outcomes of studies which evaluated this aspect of XIST application in clinical settings.

TABLE 2.

Diagnostic value of XIST in cancers.

Cancer type Numbers of clinical samples Distinguish between Area under curve Sensitivity (%) Specificity (%) References
Nasopharyngeal carcinoma (NPC) 108 pairs of NPC tissues and ANTs NPC patients vs. controls 0.813 0.886 0.795 Song et al., 2016
Early gastric cancer (EGC) 76 pairs of EGC tissues and ANTs and EGC plasma EGC patients vs. controls 0.733 0.846 0.590 Lu et al., 2017
Colorectal cancer 120 serum specimens from CRC responding and non-responding patients to 5FU treatment CRC patients showing response to 5FU treatment vs. patients showing no response 0.717 0.756 0.683 Xiao et al., 2017
Serum EVs from 94 CRC patients and 41 healthy participants CRC patients vs. healthy controls 0.864 0.883 0.902 Yu et al., 2020
Non-small cell lung cancer 32 pairs of NSCLC tumor tissues and ANTs 64 serum samples NSCLC vs. controls 0.834 0.726 0.935 Tantai et al., 2015
Breast cancer 36 serum samples from breast cancer patients and 32 control healthy subjects Breast cancer patients vs. healthy controls 0.78 0.67 0.89 Zhao et al., 2018
Thyroid cancer 77 pairs of thyroid cancer tissue samples and ANTs Thyroid cancer patients vs. healthy controls 0.7360 – – Liu et al., 2018
Open in a new tab

Discussion

Although XIST has been primarily identified as a transcript whichregulates X inactivation, subsequent studies have show thatthislncRNA has several regulatory roles beyond thisphysiologicalprocess. In addition to interacting with chromatin modifyingmolecules, XIST can be served as a molecularsponge for miRNAs to modulate expression of miRNA targets. miR-362-5p/UBAP1, miR-125b-5p/NLRC5, miR-200c-3p/ANLN, miR-337/JAK2, miR-132/PXN, miR-497/MACC1, miR-185/TGF-β1, miR-497-5p/FOXK1, miR-141-5p/TGF-β2, miR-152/KLF4, and let-7i/BAG-1 are among molecular cascades downstream of XIST which are involved in the carcinogenesis process.

XIST can modulate resistance to chemotherapeutic agents in a number of cancers including breast and lung cancers (Sun et al., 2017; Zhang et al., 2020). Thus, modulation of its expression might beregarded as a strategy for combatting chemoresistance of cancercells. However, tissue-specific effects of XIST in conferring resistance to chemotherapeutic agents should be considered. Most of the above-mentioned studies have indicated an oncogenic role for XIST. However, in prostate cancer, a single study has indicated a tumor suppressor role for this lncRNA (Du et al., 2017). Similar result has been reported for XIST in oral squamous cell carcinoma (Li et al., 2020c). In hepatocellular carcinoma, breast cancer, ovarian cancer, osteosarcoma and renal cell carcinoma, different studies have reported inconsistent results (Supplementary Table 2). Most notably, animal studies in hepatocellular carcinoma, breast cancer, ovarian cancer and osteosarcoma have indicated inconsistent results regarding the role of XIST. Although these discrepancies might be due to possible tissue-specific roles for XIST or differences in cell lines (particularly passage number) and animal models, future studies with larger sample sizes from different ethnic groups are needed to solve these discrepancies.

XIST has both diagnostic and prognostic values in different cancers, albeit the prognostic value of this lncRNA has been more validated. Both tissue and serum levels of XIST can be used to distinguish disease status, yet the latter source is superior regarding the non-invasive route of access. The best diagnostic power values have been reported in CRC, NSCLC, and nasopharyngeal carcinoma, respectively. However, all of these studies lack validation in independent samples. So, future studies should assess this aspect of XIST application in larger cohorts of patients.

In brief, XIST has been shown to affect carcinogenic process possibly in a tissue-specific manner. Therefore, therapeutic strategies targeting this lncRNA should consider this point to design a personalized regimen for treatment of cancer.

Author Contributions

MT and SG-F wrote the draft and revised it. SD, MF, and SM collected the data and designed the tables and figures. All the authors approved submitted version.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2021.690522/full#supplementary-material

Click here for additional data file. (60KB, docx)
Click here for additional data file. (58.2KB, docx)

References

  1. Brown C. J., Hendrich B. D., Rupert J. L., Lafrenière R. G., Xing Y., Lawrence J., et al. (1992). The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus. Cell 71 527–542. 10.1016/0092-8674(92)90520-M [DOI] [PubMed] [Google Scholar]
  2. Chang S., Chen B., Wang X., Wu K., Sun Y. (2017). Long non-coding RNA XIST regulates PTEN expression by sponging miR-181a and promotes hepatocellular carcinoma progression. BMC Cancer 17:248. 10.1186/s12885-017-3216-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chen D., Chen T., Guo Y., Wang C., Dong L., Lu C. (2020). Platycodin D (PD) regulates LncRNA-XIST/miR-335 axis to slow down bladder cancer progression in vitro and in vivo. Exper. Cell Res. 396:112281. 10.1016/j.yexcr.2020.112281 [DOI] [PubMed] [Google Scholar]
  4. Chen D.-L., Chen L.-Z., Lu Y.-X., Zhang D.-S., Zeng Z.-L., Pan Z.-Z., et al. (2017). Long noncoding RNA XIST expedites metastasis and modulates epithelial–mesenchymal transition in colorectal cancer. Cell Death Dis. 8:e3011. 10.1038/cddis.2017.421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen D.-L., Ju H.-Q., Lu Y.-X., Chen L.-Z., Zeng Z.-L., Zhang D.-S., et al. (2016). Long non-coding RNA XIST regulates gastric cancer progression by acting as a molecular sponge of miR-101 to modulate EZH2 expression. J. Exper. Clin. Cancer Res. 35:142. 10.1186/s13046-016-0420-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen X., Xiong D., Ye L., Wang K., Huang L., Mei S., et al. (2019). Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1. Cancer Cell Intern. 19 1–19. 10.1186/s12935-019-0744-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen Z., Hu X., Wu Y., Cong L., He X., Lu J., et al. (2019). Long non-coding RNA XIST promotes the development of esophageal cancer by sponging miR-494 to regulate CDK6 expression. Biomed. Pharmacother. 109 2228–2236. 10.1016/j.biopha.2018.11.049 [DOI] [PubMed] [Google Scholar]
  8. Cheng Q., Xu X., Jiang H., Xu L., Li Q. (2018). Knockdown of long non-coding RNA XIST suppresses nasopharyngeal carcinoma progression by activating miR-491-5p. J. Cell. Biochem. 119 3936–3944. 10.1002/jcb.26535 [DOI] [PubMed] [Google Scholar]
  9. Cheng Y., Chang Q., Zheng B., Xu J., Li H., Wang R. (2019). LncRNA XIST promotes the epithelial to mesenchymal transition of retinoblastoma via sponging miR-101. Eur. J. Pharmacol. 843 210–216. 10.1016/j.ejphar.2018.11.028 [DOI] [PubMed] [Google Scholar]
  10. Cheng Z., Li Z., Ma K., Li X., Tian N., Duan J., et al. (2017). Long non-coding RNA XIST promotes glioma tumorigenicity and angiogenesis by acting as a molecular sponge of miR-429. J. Cancer 8:4106. 10.7150/jca.21024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cheng Z., Luo C., Guo Z. (2020). LncRNA-XIST/microRNA-126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma. J. Cell. Biochem. 121 2170–2183. 10.1002/jcb.29440 [DOI] [PubMed] [Google Scholar]
  12. Chu C., Zhang Q. C., da Rocha S. T., Flynn R. A., Bharadwaj M., Calabrese J. M., et al. (2015). Systematic discovery of Xist RNA binding proteins. Cell 161 404–416. 10.1016/j.cell.2015.03.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Du P., Zhao H., Peng R., Liu Q., Yuan J., Peng G., et al. (2017). LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci. Rep. 37:BSR20170696. 10.1042/BSR20170696 [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Du Y., Weng X.-D., Wang L., Liu X.-H., Zhu H.-C., Guo J., et al. (2017). LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression. Oncotarget 8:94358. 10.18632/oncotarget.21719 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Du Y.-L., Liang Y., Cao Y., Liu L., Li J., Shi G.-Q. (2020). LncRNA XIST promotes migration and invasion of papillary thyroid cancer cell by modulating MiR-101-3p/CLDN1 axis. Biochem. Genet. 59 437–452. 10.1007/s10528-020-09985-8 [DOI] [PubMed] [Google Scholar]
  16. Fang H., Yang L., Fan Y., Mo C., Luo L., Liang D., et al. (2020). Upregulation of tissue long noncoding RNA X inactive specific transcript predicts poor postoperative survival in patients with non-small cell lung cancer. Medicine 99 e21789. 10.1097/MD.0000000000021789 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Fang J., Sun C.-C., Gong C. (2016). Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression. Biochem. Biophys. Res. Commun. 478 811–817. 10.1016/j.bbrc.2016.08.030 [DOI] [PubMed] [Google Scholar]
  18. Gao W., Gao J., Chen L., Ren Y., Ma J. (2019). Targeting XIST induced apoptosis of human osteosarcoma cells by activation of NF-kB/PUMA signal. Bioengineered 10 261–270. 10.1080/21655979.2019.1631104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gong M., Wang X., Mu L., Wang Y., Pan J., Yuan X., et al. (2020). SRC-1 enhances the stemness of glioblastoma by activating lncRNA XIST/ miR-152/ KLF4 pathway. Cancer Sci. 112 604–618. 10.1111/cas.14685 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Guo T., Yuan D., Zhang W., Zhu D., Xiao A., Mao G., et al. (2021). Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a. Hum. Cell 34 579–587. 10.1007/s13577-020-00469-w [DOI] [PubMed] [Google Scholar]
  21. Hai B., Pan X., Du C., Mao T., Jia F., Liu Y., et al. (2020). LncRNA XIST promotes growth of human chordoma cells by regulating miR-124-3p/iASPP pathway. Oncotargets Therapy 13:4755. 10.2147/OTT.S252195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Han Q., Li L., Liang H., Li Y., Xie J., Wang Z. (2017). Downregulation of lncRNA X inactive specific transcript (XIST) suppresses cell proliferation and enhances radiosensitivity by upregulating mir-29c in nasopharyngeal carcinoma cells. Med. Sci. Monit. 23:4798. 10.12659/MSM.905370 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hu B., Shi G., Li Q., Li W., Zhou H. (2019). Long noncoding RNA XIST participates in bladder cancer by downregulating p53 via binding to TET1. J. Cell. Biochem. 120 6330–6338. 10.1002/jcb.27920 [DOI] [PubMed] [Google Scholar]
  24. Hu C., Liu S., Han M., Wang Y., Xu C. (2018). Knockdown of lncRNA XIST inhibits retinoblastomaprogression by modulating the miR-124/STAT3 axis. Biomed. Pharmacother. 107 547–554. 10.1016/j.biopha.2018.08.020 [DOI] [PubMed] [Google Scholar]
  25. Hu Y., Deng C., Zhang H., Zhang J., Peng B., Hu C. (2017). Long non-coding RNA XIST promotes cell growth and metastasis through regulating miR-139-5p mediated Wnt/β-catenin signaling pathway in bladder cancer. Oncotarget 8:94554. 10.18632/oncotarget.21791 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  26. Huang R., Zhu L., Zhang Y. (2020). XIST lost induces ovarian cancer stem cells to acquire taxol resistance via a KMT2C-dependent way. Cancer Cell Intern. 20 1–11. 10.1186/s12935-020-01500-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Huang Y.-S., Chang C.-C., Lee S.-S., Jou Y.-S., Shih H.-M. (2016). Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression. Oncotarget 7:43256. 10.18632/oncotarget.9673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jiang H., Zhang H., Hu X., Li W. (2018). Knockdown of long non-coding RNA XIST inhibits cell viability and invasion by regulating miR-137/PXN axis in non-small cell lung cancer. Intern. J. Biol. Macromol. 111 623–631. 10.1016/j.ijbiomac.2018.01.022 [DOI] [PubMed] [Google Scholar]
  29. Jiang Q., Xing W., Cheng J., Yu Y. (2020). Knockdown of lncRNA XIST suppresses cell tumorigenicity in human non-small cell lung cancer by regulating miR-142-5p/PAX6 Axis. Oncotargets Therapy 13:4919. 10.2147/OTT.S238808 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kobayashi R., Miyagawa R., Yamashita H., Morikawa T., Okuma K., Fukayama M., et al. (2016). Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. Oncol. Lett. 12 3066–3074. 10.3892/ol.2016.5054 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kong Q., Zhang S., Liang C., Zhang Y., Kong Q., Chen S., et al. (2018). LncRNA XIST functions as a molecular sponge of miR-194-5p to regulate MAPK1 expression in hepatocellular carcinoma cell. J. Cell. Biochem. 119 4458–4468. 10.1002/jcb.26540 [DOI] [PubMed] [Google Scholar]
  32. Li C., Wan L., Liu Z., Xu G., Wang S., Su Z., et al. (2018). Long non-coding RNA XIST promotes TGF-β-induced epithelial-mesenchymal transition by regulating miR-367/141-ZEB2 axis in non-small-cell lung cancer. Cancer Lett. 418 185–195. 10.1016/j.canlet.2018.01.036 [DOI] [PubMed] [Google Scholar]
  33. Li G., Wu Y., Li Y., Li J. (2017). High expression of long non-coding RNA XIST in osteosarcoma is associated with cell proliferation and poor prognosis. Eur. Rev. Med. Pharmacol. Sci. 21 2829–2834. [PubMed] [Google Scholar]
  34. Li H., Cui J., Xu B., He S., Yang H., Liu L. (2019). Long non-coding RNA XIST serves an oncogenic role in osteosarcoma by sponging miR-137. Exper. Therap. Med. 17 730–738. 10.3892/etm.2018.7032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Li J., He D. (2019). Long noncoding RNA Xist predicts the presence of lymph node metastases in human oesophageal squamous cell carcinoma. Br. J. Biomed. Sci. 76 147–149. 10.1080/09674845.2019.1594489 [DOI] [PubMed] [Google Scholar]
  36. Li P., Wang L., Li P., Hu F., Cao Y., Tang D., et al. (2020a). Silencing lncRNA XIST exhibits antiproliferative and proapoptotic effects on gastric cancer cells by up-regulating microRNA-132 and down-regulating PXN. Aging 12:635. 10.18632/aging.103635 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  37. Li P., Wang L., Li P., Hu F., Cao Y., Tang D., et al. (2020b). Silencing of long non-coding RNA XIST represses gastric cancer progression through blocking NFκB pathway via inhibiting HNF4A-mediated transcription of EPHA1. Cancer Gene Therapy 28 307–320. 10.1038/s41417-020-00220-5 [DOI] [PubMed] [Google Scholar]
  38. Li Q., Sun Q., Zhu B. (2020c). LncRNA XIST inhibits the progression of oral squamous cell carcinoma via sponging miR-455-3p/BTG2 Axis. Oncotargets Therapy 13:11211. 10.2147/OTT.S267937 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Li X., Hou L., Yin L., Zhao S. (2020d). LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer. J. Biosci. 45 1–11. 10.1007/s12038-020-9999-7 [DOI] [PubMed] [Google Scholar]
  40. Liang S., Gong X., Zhang G., Huang G., Lu Y., Li Y. (2017). The lncRNA XIST interacts with miR-140/miR-124/iASPP axis to promote pancreatic carcinoma growth. Oncotarget 8:113701. 10.18632/oncotarget.22555 [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Lin X.-Q., Huang Z.-M., Chen X., Wu F., Wu W. (2018). XIST induced by JPX suppresses hepatocellular carcinoma by sponging miR-155-5p. Yonsei Med. J. 59:816. 10.3349/ymj.2018.59.7.816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Liu A., Liu L., Lu H. (2019). LncRNA XIST facilitates proliferation and epithelial–mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2. J. Cell. Physiol. 234 13747–13761. 10.1002/jcp.28054 [DOI] [PubMed] [Google Scholar]
  43. Liu B., Luo C., Lin H., Ji X., Zhang E., Li X. (2020). Long noncoding RNA XIST acts as a ceRNA of miR-362-5p to suppress breast cancer progression. Cancer Biother. Radiopharm. 10.1089/cbr.2019.3481[Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  44. Liu C., Lu Z., Liu H., Zhuang S., Guo P. (2020). LncRNA XIST promotes the progression of laryngeal squamous cell carcinoma via sponging miR-125b-5p to modulate TRIB2. Biosci. Rep. 40:BSR20193172. 10.1042/BSR20193172 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  45. Liu H., Deng H., Zhao Y., Li C., Liang Y. (2018). LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling. J. Exper. Clin. Cancer Res. 37 1–12. 10.1186/s13046-018-0950-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Liu J., Yao L., Zhang M., Jiang J., Yang M., Wang Y. (2019). Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic cell death. Aging 11:7830. 10.18632/aging.102291 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Liu P., Pan Y., Wang D., You D. (2020). Long non-coding RNA XIST promotes cell proliferation of pancreatic cancer through miR-137 and Notch1 pathway. Eur. Rev. Med. Pharmacol. Sci. 24 12161–12170. [DOI] [PubMed] [Google Scholar]
  48. Liu X., Cui L., Hua D. (2018). Long noncoding RNA XIST regulates miR-137-EZH2 Axis to promote tumor metastasis in colorectal cancer. Oncol. Res. Featur. Preclinic. Clin. Cancer Therap. 27 99–106. 10.3727/096504018X15195193936573 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  49. Liu X., Xie S., Zhang J., Kang Y. (2020). Long noncoding RNA XIST contributes to cervical cancer development through targeting miR-889-3p/SIX1 axis. Cancer Biother. Radiopharm. 35 640–649. 10.1089/cbr.2019.3318 [DOI] [PubMed] [Google Scholar]
  50. Loda A., Heard E. (2019). Xist RNA in action: past, present, and future. PLoS Genet. 15:e1008333. 10.1371/journal.pgen.1008333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Lu Q., Yu T., Ou X., Cao D., Xie T., Chen X. (2017). Potential lncRNA diagnostic biomarkers for early gastric cancer. Mol. Med. Rep. 16 9545–9552. 10.3892/mmr.2017.7770 [DOI] [PubMed] [Google Scholar]
  52. Lv G.-Y., Miao J., Zhang X.-L. (2017). Long noncoding RNA XIST promotes osteosarcoma progression by targeting Ras-related protein RAP2B via miR-320b. Oncol. Res. 26 837–846. 10.3727/096504017X14920318811721 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Lyu X., Ma Y., Wu F., Wang L., Wang L. (2019). LncRNA NKILA inhibits retinoblastoma by downregulating lncRNA XIST. Curr. Eye Res. 44 975–979. 10.1080/02713683.2019.1606253 [DOI] [PubMed] [Google Scholar]
  54. Ma L., Zhou Y., Luo X., Gao H., Deng X., Jiang Y. (2017). Long non-coding RNA XIST promotes cell growth and invasion through regulating miR-497/MACC1 axis in gastric cancer. Oncotarget 8:4125. 10.18632/oncotarget.13670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Ma W., Wang H., Jing W., Zhou F., Chang L., Hong Z., et al. (2017). Downregulation of long non-coding RNAs JPX and XIST is associated with the prognosis of hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 41 163–170. 10.1016/j.clinre.2016.09.002 [DOI] [PubMed] [Google Scholar]
  56. Marahrens Y., Panning B., Dausman J., Strauss W., Jaenisch R. (1997). Xist-deficient mice are defective in dosage compensation but not spermatogenesis. Genes Dev. 11 156–166. 10.1101/gad.11.2.156 [DOI] [PubMed] [Google Scholar]
  57. McHugh C. A., Chen C.-K., Chow A., Surka C. F., Tran C., McDonel P., et al. (2015). The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. Nature 521 232–236. 10.1038/nature14443 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Mo Y., Lu Y., Wang P., Huang S., He L., Li D., et al. (2017). Long non-coding RNA XIST promotes cell growth by regulating miR-139-5p/PDK1/AKT axis in hepatocellular carcinoma. Tumor Biol. 39:1010428317690999. 10.1177/1010428317690999 [DOI] [PubMed] [Google Scholar]
  59. Pan B., Lin X., Zhang L., Hong W., Zhang Y. (2019). Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance. Melanoma Res. 29 254–262. 10.1097/CMR.0000000000000560 [DOI] [PubMed] [Google Scholar]
  60. Penny G. D., Kay G. F., Sheardown S. A., Rastan S., Brockdorff N. (1996). Requirement for Xist in X chromosome inactivation. Nature 379 131–137. 10.1038/379131a0 [DOI] [PubMed] [Google Scholar]
  61. Qiu H., Yang K., Yu H., Liu M. (2019). Downregulation of long non-coding RNA XIST inhibits cell proliferation, migration, invasion and EMT by regulating miR-212-3p/CBLL1 axis in non-small cell lung cancer cells. Eur. Rev. Med. Pharmacol. Sci. 23 8391–8402. [DOI] [PubMed] [Google Scholar]
  62. Shen J., Hong L., Yu D., Cao T., Zhou Z., He S. (2019). LncRNA XIST promotes pancreatic cancer migration, invasion and EMT by sponging miR-429 to modulate ZEB1 expression. Intern. J. Biochem. Cell Biol. 113 17–26. 10.1016/j.biocel.2019.05.021 [DOI] [PubMed] [Google Scholar]
  63. Shen J., Xiong J., Shao X., Cheng H., Fang X., Sun Y., et al. (2020). Knockdown of the long noncoding RNA XIST suppresses glioma progression by upregulating miR-204-5p. J. Cancer 11:4550. 10.7150/jca.45676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Shi J., Tan S., Song L., Song L., Wang Y. (2020). LncRNA XIST knockdown suppresses the malignancy of human nasopharyngeal carcinoma through XIST/miRNA-148a-3p/ADAM17 pathway in vitro and in vivo. Biomed. Pharmacother. 121:109620. 10.1016/j.biopha.2019.109620 [DOI] [PubMed] [Google Scholar]
  65. Song H., He P., Shao T., Li Y., Li J., Zhang Y. (2017). Long non-coding RNA XIST functions as an oncogene in human colorectal cancer by targeting miR-132-3p. J. Buon. 22 696–703. [PubMed] [Google Scholar]
  66. Song P., Ye L.-F., Zhang C., Peng T., Zhou X.-H. (2016). Long non-coding RNA XIST exerts oncogenic functions in human nasopharyngeal carcinoma by targeting miR-34a-5p. Gene 592 8–14. 10.1016/j.gene.2016.07.055 [DOI] [PubMed] [Google Scholar]
  67. Sun J., Zhang Y. (2019). LncRNA XIST enhanced TGF-β2 expression by targeting miR-141-3p to promote pancreatic cancer cells invasion. Biosci. Rep. 39:BSR20190332. 10.1042/BSR20190332 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Sun J., Pan L.-M., Chen L.-B., Wang Y. (2017). LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle 16 2100–2107. 10.1080/15384101.2017.1361071 [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Sun K., Jia Z., Duan R., Yan Z., Jin Z., Yan L., et al. (2019). Long non-coding RNA XIST regulates miR-106b-5p/P21 axis to suppress tumor progression in renal cell carcinoma. Biochem. Biophys. Res. Commun. 510 416–420. 10.1016/j.bbrc.2019.01.116 [DOI] [PubMed] [Google Scholar]
  70. Sun N., Zhang G., Liu Y. (2018). Long non-coding RNA XIST sponges miR-34a to promotes colon cancer progression via Wnt/β-catenin signaling pathway. Gene 665 141–148. 10.1016/j.gene.2018.04.014 [DOI] [PubMed] [Google Scholar]
  71. Sun W., Zu Y., Fu X., Deng Y. (2017). Knockdown of lncRNA-XIST enhances the chemosensitivity of NSCLC cells via suppression of autophagy. Oncol. Rep. 38 3347–3354. 10.3892/or.2017.6056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Sun X., Wei B., Peng Z.-H., Fu Q.-L., Wang C.-J., Zheng J.-C., et al. (2019). Knockdown of lncRNA XIST suppresses osteosarcoma progression by inactivating AKT/mTOR signaling pathway by sponging miR-375-3p. Intern. J. Clin. Exper. Pathol. 12:1507. [PMC free article] [PubMed] [Google Scholar]
  73. Sun Z., Zhang B., Cui T. (2018). Long non-coding RNA XIST exerts oncogenic functions in pancreatic cancer via miR-34a-5p. Oncol. Rep. 39 1591–1600. 10.3892/or.2018.6245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Tang Y., He R., An J., Deng P., Huang L., Yang W. (2017). lncRNA XIST interacts with miR-140 to modulate lung cancer growth by targeting iASPP. Oncol. Rep. 38 941–948. 10.3892/or.2017.5751 [DOI] [PubMed] [Google Scholar]
  75. Tantai J., Hu D., Yang Y., Geng J. (2015). Combined identification of long non-coding RNA XIST and HIF1A-AS1 in serum as an effective screening for non-small cell lung cancer. Intern. J. Clin. Exper. Pathol. 8:7887. [PMC free article] [PubMed] [Google Scholar]
  76. Tian L.-J., Wu Y.-P., Wang D., Zhou Z.-H., Xue S.-B., Zhang D.-Y., et al. (2019). Upregulation of long noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is associated with cisplatin resistance in non-small cell lung cancer (NSCLC) by downregulating MicroRNA-144-3p. Med. Sci. Monitor 25:8095. 10.12659/MSM.916075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Wang C., Li L., Li M., Wang W., Liu Y., Wang S. (2020a). Silencing long non-coding RNA XIST suppresses drug resistance in acute myeloid leukemia through down-regulation of MYC by elevating microRNA-29a expression. Mol. Med. 26 1–11. 10.1186/s10020-020-00229-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Wang C., Qi S., Xie C., Li C., Wang P., Liu D. (2018). Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p. J. Gynecol. Oncol. 29:e99. 10.3802/jgo.2018.29.e99 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Wang H., Shen Q., Zhang X., Yang C., Cui S., Sun Y., et al. (2017). The long non-coding RNA XIST controls non-small cell lung cancer proliferation and invasion by modulating miR-186-5p. Cell. Physiol. Biochem. 41 2221–2229. 10.1159/000475637 [DOI] [PubMed] [Google Scholar]
  80. Wang J., Cai H., Dai Z., Wang G. (2019). Down-regulation of lncRNA XIST inhibits cell proliferation via regulating miR-744/RING1 axis in non-small cell lung cancer. Clin. Sci. 133 1567–1579. 10.1042/CS20190519 [DOI] [PubMed] [Google Scholar]
  81. Wang N., He J.-X., Jia G.-Z., Wang K., Zhou S., Wu T., et al. (2020b). The lncRNA XIST promotes colorectal cancer cell growth through regulating the miR-497-5p/FOXK1 axis. Cancer Cell Intern. 20 1–11. 10.1186/s12935-020-01647-4 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  82. Wang W., Shen H., Cao G., Huang J. (2019). Long non-coding RNA XIST predicts poor prognosis and promotes malignant phenotypes in osteosarcoma. Oncol. Lett. 17 256–262. 10.3892/ol.2018.9596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Wang X., Zhang G., Cheng Z., Dai L., Jia L., Jing X., et al. (2018). Knockdown of LncRNA-XIST suppresses proliferation and TGF-β1-induced EMT in NSCLC through the notch-1 pathway by regulation of miR-137. Genet. Test. Mol. Biomark. 22 333–342. 10.1089/gtmb.2018.0026 [DOI] [PubMed] [Google Scholar]
  84. Wang Y., Li H., Chen J., Kong F., Mo Z., Wang J., et al. (2020c). Overexpression of XIST facilitates cell proliferation, invasion and suppresses cell apoptosis by reducing radio-sensitivity of glioma cells via miR-329-3p/CREB1 axis. Eur. Rev. Med. Pharmacol. Sci. 24 3190–3203. [DOI] [PubMed] [Google Scholar]
  85. Wang Y., Sun D., Sheng Y., Guo H., Meng F., Song T. (2020d). XIST promotes cell proliferation and invasion by regulating miR-140-5p and SOX4 in retinoblastoma. World J. Surg. Oncol. 18 1–8. 10.1186/s12957-020-01825-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Wang Z., Yuan J., Li L., Yang Y., Xu X., Wang Y. (2017). Long non-coding RNA XIST exerts oncogenic functions in human glioma by targeting miR-137. Am. J. Transl. Res. 9:1845. [PMC free article] [PubMed] [Google Scholar]
  87. Wei W., Liu Y., Lu Y., Yang B., Tang L. (2017). LncRNA XIST promotes pancreatic cancer proliferation through miR-133a/EGFR. J. Cell. Biochem. 118 3349–3358. 10.1002/jcb.25988 [DOI] [PubMed] [Google Scholar]
  88. Wen J. F., Jiang Y. Q., Li C., Dai X. K., Wu T., Yin W. Z. (2020). LncRNA-XIST promotes the oxidative stress-induced migration, invasion, and epithelial-to-mesenchymal transition of osteosarcoma cancer cells through miR-153-SNAI1 axis. Cell Biol. Intern. 44 1991–2001. 10.1002/cbin.11405 [DOI] [PubMed] [Google Scholar]
  89. Wu X., Dinglin X., Wang X., Luo W., Shen Q., Li Y., et al. (2017). Long noncoding RNA XIST promotes malignancies of esophageal squamous cell carcinoma via regulation of miR-101/EZH2. Oncotarget 8:76015. 10.18632/oncotarget.18638 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Xiao D., Cui X., Wang X. (2019). Long noncoding RNA XIST increases the aggressiveness of laryngeal squamous cell carcinoma by regulating miR-124-3p/EZH2. Exper. Cell Res. 381 172–178. 10.1016/j.yexcr.2019.04.034 [DOI] [PubMed] [Google Scholar]
  91. Xiao Y., Yurievich U. A., Yosypovych S. V. (2017). Long noncoding RNA XIST is a prognostic factor in colorectal cancer and inhibits 5-fluorouracil-induced cell cytotoxicity through promoting thymidylate synthase expression. Oncotarget 8:83171. 10.18632/oncotarget.20487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Xing F., Liu Y., Wu S.-Y., Wu K., Sharma S., Mo Y.-Y., et al. (2018). Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78 4316–4330. 10.1158/0008-5472.CAN-18-1102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Xiong Y., Wang L., Li Y., Chen M., He W., Qi L. (2017). The long non-coding RNA XIST interacted with MiR-124 to modulate bladder cancer growth, invasion and migration by targeting androgen receptor (AR). Cell. Physiol. Biochem. 43 405–418. 10.1159/000480419 [DOI] [PubMed] [Google Scholar]
  94. Xu R., Zhu X., Chen F., Huang C., Ai K., Wu H., et al. (2018). LncRNA XIST/miR-200c regulates the stemness properties and tumourigenicity of human bladder cancer stem cell-like cells. Cancer Cell Intern. 18 1–10. 10.1186/s12935-018-0540-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Xu T., Jiang W., Fan L., Gao Q., Li G. (2017). Upregulation of long noncoding RNA Xist promotes proliferation of osteosarcoma by epigenetic silencing of P21. Oncotarget 8:101406. 10.18632/oncotarget.20738 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Xu X., Zhou X., Chen Z., Gao C., Zhao L., Cui Y. (2020). Silencing of lncRNA XIST inhibits non-small cell lung cancer growth and promotes chemosensitivity to cisplatin. Aging 12:4711. 10.18632/aging.102673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Xu Y., Wang J., Wang J. (2018). Long noncoding RNA XIST promotes proliferation and invasion by targeting miR-141 in papillary thyroid carcinoma. Oncotargets Therapy 11:5035. 10.2147/OTT.S170439 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Xu Z., Xu J., Lu H., Lin B., Cai S., Guo J., et al. (2017). LARP1 is regulated by the XIST/miR-374a axis and functions as an oncogene in non-small cell lung carcinoma. Oncol. Rep. 38 3659–3667. 10.3892/or.2017.6040 [DOI] [PubMed] [Google Scholar]
  99. Yang C., Wu K., Wang S., Wei G. (2018). Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p. J. Cell. Biochem. 119 5646–5656. 10.1002/jcb.26743 [DOI] [PubMed] [Google Scholar]
  100. Yang H., Zhang X., Zhao Y., Sun G., Zhang J., Gao Y., et al. (2020). Downregulation of lncRNA XIST represses tumor growth and boosts radiosensitivity of neuroblastoma via modulation of the miR-375/L1CAM Axis. Neurochem. Res. 45 2679–2690. 10.1007/s11064-020-03117-9 [DOI] [PubMed] [Google Scholar]
  101. Yang L. G., Cao M. Z., Zhang J., Li X. Y., Sun Q. L. (2020). LncRNA XIST modulates HIF-1A/AXL signaling pathway by inhibiting miR-93-5p in colorectal cancer. Mol. Genet. Genom. Med. 8:e1112. 10.1002/mgg3.1112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Yao L., Yang L., Song H., Liu T., Yan H. (2020). Silencing of lncRNA XIST suppresses proliferation and autophagy and enhances vincristine sensitivity in retinoblastoma cells by sponging miR-204-5p. Eur. Rev. Med. Pharmacol. Sci. 24 3526–3537. [DOI] [PubMed] [Google Scholar]
  103. Yao Y., Ma J., Xue Y., Wang P., Li Z., Liu J., et al. (2015). Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett. 359 75–86. 10.1016/j.canlet.2014.12.051 [DOI] [PubMed] [Google Scholar]
  104. Yu H., Xue Y., Wang P., Liu X., Ma J., Zheng J., et al. (2017). Knockdown of long non-coding RNA XIST increases blood–tumor barrier permeability and inhibits glioma angiogenesis by targeting miR-137. Oncogenesis 6:e303. 10.1038/oncsis.2017.7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Yu J., Dong W., Liang J. (2020). Extracellular vesicle-transported long non-coding RNA (LncRNA) X inactive-specific transcript (XIST) in Serum is a potential novel biomarker for colorectal cancer diagnosis. Med. Sci. Monitor 26:e0924448-41. 10.12659/MSM.924448 [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Zhang J., Cao Z., Ding X., Wei X., Zhang X., Hou J., et al. (2017). The lncRNA XIST regulates the tumorigenicity of renal cell carcinoma cells via the miR-302c/SDC1 axis. Intern. J. Clin. Exper. Pathol. 10:7481. [PMC free article] [PubMed] [Google Scholar]
  107. Zhang J., Li W.-Y., Yang Y., Yan L.-Z., Zhang S.-Y., He J., et al. (2019). LncRNA XIST facilitates cell growth, migration and invasion via modulating H3 histone methylation of DKK1 in neuroblastoma. Cell Cycle 18 1882–1892. 10.1080/15384101.2019.1632134 [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Zhang M., Wang F., Xiang Z., Huang T., Zhou W. B. (2020). LncRNA XIST promotes chemoresistance of breast cancer cells to doxorubicin by sponging miR-200c-3p to upregulate ANLN. Clin. Exper. Pharmacol. Physiol. 47 1464–1472. 10.1111/1440-1681.13307 [DOI] [PubMed] [Google Scholar]
  109. Zhang Q., Chen B., Liu P., Yang J. (2018). XIST promotes gastric cancer (GC) progression through TGF-β1 via targeting miR-185. J. Cell. Biochem. 119 2787–2796. 10.1002/jcb.26447 [DOI] [PubMed] [Google Scholar]
  110. Zhang R., Xia T. (2017). Long non-coding RNA XIST regulates PDCD4 expression by interacting with miR-21-5p and inhibits osteosarcoma cell growth and metastasis. Intern. J. Oncol. 51 1460–1470. 10.3892/ijo.2017.4127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Zhang R., Wang Z., Yu Q., Shen J., He W., Zhou D., et al. (2019). Atractylenolide II reverses the influence of lncRNA XIST/miR-30a-5p/ROR1 axis on chemo-resistance of colorectal cancer cells. J. Cell. Mol. Med. 23 3151–3165. 10.1111/jcmm.14148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Zhang X.-T., Pan S.-X., Wang A.-H., Kong Q.-Y., Jiang K.-T., Yu Z.-B. (2019). Long non-coding RNA (lncRNA) X-Inactive Specific Transcript (XIST) plays a critical role in predicting clinical prognosis and progression of colorectal cancer. Med. Sci. Monitor 25:6429. 10.12659/MSM.915329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Zhang Y., Zhu Z., Huang S., Zhao Q., Huang C., Tang Y., et al. (2019). lncRNA XIST regulates proliferation and migration of hepatocellular carcinoma cells by acting as miR-497-5p molecular sponge and targeting PDCD4. Cancer Cell Intern. 19 1–13. 10.1186/s12935-019-0909-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Zhang Y.-L., Li X.-B., Hou Y.-X., Fang N.-Z., You J.-C., Zhou Q.-H. (2017). The lncRNA XIST exhibits oncogenic properties via regulation of miR-449a and Bcl-2 in human non-small cell lung cancer. Acta Pharmacol. Sinica 38 371–381. 10.1038/aps.2016.133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Zhao C., Bai X., Hu X. (2020). Knockdown of lncRNA XIST inhibits hypoxia-induced glycolysis, migration and invasion through regulating miR-381-3p/NEK5 axis in nasopharyngeal carcinoma. Eur. Rev. Med. Pharmacol. Sci. 24 2505–2517. [DOI] [PubMed] [Google Scholar]
  116. Zhao L., Zhao Y., He Y., Li Q., Mao Y. (2018). The functional pathway analysis and clinical significance of miR-20a and its related lncRNAs in breast cancer. Cell. Signal. 51 152–165. 10.1016/j.cellsig.2018.08.004 [DOI] [PubMed] [Google Scholar]
  117. Zhao Y., Yu Z., Ma R., Zhang Y., Zhao L., Yan Y., et al. (2020). LncRNA-Xist/miR-101-3p/KLF6-C/EBPα axis promotes TAMs polarization to regulate cancer cells proliferation and migration. Mol. Therapy Nucleic Acids 23 536–551. 10.1016/j.omtn.2020.12.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Zheng R., Lin S., Guan L., Yuan H., Liu K., Liu C., et al. (2018). Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem. Biophys. Res. Commun. 498 1002–1008. 10.1016/j.bbrc.2018.03.104 [DOI] [PubMed] [Google Scholar]
  119. Zheng W., Li J., Zhou X., Cui L., Wang Y. (2020). The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337. Arab J. Gastroenterol. 21 199–206. 10.1016/j.ajg.2020.07.010 [DOI] [PubMed] [Google Scholar]
  120. Zhou K., Li S., Du G., Fan Y., Wu P., Sun H., et al. (2019a). LncRNA XIST depletion prevents cancer progression in invasive pituitary neuroendocrine tumor by inhibiting bFGF via upregulation of microRNA-424-5p. Oncotargets Therapy 12:7095. 10.2147/OTT.S208329 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  121. Zhou K., Yang J., Li X., Chen W. (2019b). Long non-coding RNA XIST promotes cell proliferation and migration through targeting miR-133a in bladder cancer. Exper. Therap. Med. 18 3475–3483. 10.3892/etm.2019.7960 [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Zhou X., Xu X., Gao C., Cui Y. (2019c). XIST promote the proliferation and migration of non-small cell lung cancer cells via sponging miR-16 and regulating CDK8 expression. Am. J. Transl. Res. 11:6196. [PMC free article] [PubMed] [Google Scholar]
  123. Zhu H., Zheng T., Yu J., Zhou L., Wang L. (2018). LncRNA XIST accelerates cervical cancer progression via upregulating Fus through competitively binding with miR-200a. Biomed. Pharmacother. 105 789–797. 10.1016/j.biopha.2018.05.053 [DOI] [PubMed] [Google Scholar]
  124. Zhu J., Zhang R., Yang D., Li J., Yan X., Jin K., et al. (2018). Knockdown of long non-coding RNA XIST inhibited doxorubicin resistance in colorectal cancer by upregulation of miR-124 and downregulation of SGK1. Cell. Physiol. Biochem. 51 113–128. 10.1159/000495168 [DOI] [PubMed] [Google Scholar]
  125. Zhuang L., Yang Y., Ma X., Han B., Wang Z., Zhao Q., et al. (2016). MicroRNA-92b promotes hepatocellular carcinoma progression by targeting Smad7 and is mediated by long non-coding RNA XIST. Cell Death Dis. 7:e2203. 10.1038/cddis.2016.100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Zong Y., Zhang Y., Hou D., Xu J., Cui F., Qin Y., et al. (2020). The lncRNA XIST promotes the progression of breast cancer by sponging miR-125b-5p to modulate NLRC5. Am. J. Transl. Res. 12:3501. [PMC free article] [PubMed] [Google Scholar]
  127. Zou L., Chen F.-R., Xia R.-P., Wang H.-W., Xie Z.-R., Xu Y., et al. (2020). Long noncoding RNA XIST regulates the EGF receptor to promote TGF-β1-induced epithelial–mesenchymal transition in pancreatic cancer. Biochem. Cell Biol. 98 267–276. 10.1139/bcb-2018-0274 [DOI] [PubMed] [Google Scholar]
  128. Zuo K., Zhao Y., Zheng Y., Chen D., Liu X., Du S., et al. (2019). Long non-coding RNA XIST promotes malignant behavior of epithelial ovarian cancer. Oncotargets Therapy 12:7261. 10.2147/OTT.S204369 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (60KB, docx)
Click here for additional data file. (58.2KB, docx)

Articles from Frontiers in Cell and Developmental Biology are provided here courtesy of Frontiers Media SA

RESOURCES